A collaboration of more than 130 institutions analyzing data from more than 200,000 people found two new genetic markers increasing a woman’s risk of developing ovarian cancer. New risk-modifying loci were identified for breast (n = 1) and ovarian (n = 2) cancers in BRCA1 mutation carriers and for breast cancer (n = 1) in … Continued
As part of a huge international effort involving more than 100 institutions and genetic tests on 200,000 people, researchers have discovered dozens of signposts in DNA that can help reveal further a person’s risk for breast, ovarian or prostate cancer. The OCRF-funded Ovarian Cancer Association Consortium contributed to the ovarian cancer-related findings: five new genetic … Continued
A frequent New York Times commenter on important ovarian cancer issues, OCRF wrote a Letter to the Editor in response to the NYT editorial, “Inadequate Treatment of Ovarian Cancer,” which was published in print and online on March 21, 2013. We are grateful for the opportunity to reach such a large audience regarding the importance of seeking … Continued
A study by researchers from the Fred HutchinsonCancer Research Center in Seattle found that women working the night shift may be at higher risk for ovarian cancer. The study of 3,322 women was published in the Journal of Occupational and Environmental Medicine. NIght shift work was associated with a 24 percent higher risk of advanced ovarian … Continued
In research published online on March 11, 2013 in the Journal of Clinical Oncology, researchers report on the results of a phase III, double-blind, placebo-controlled multicenter study that evaluated whether using abagovomab as maintenance therapy prolongs recurrence-free survival and overall survival in patients with ovarian cancer in patients in their first remission. This clinical trial was … Continued
From March 9-12, 2013 top women’s cancer doctors from all over the world met in Los Angeles for the Society of Gynecologic Oncology‘s Annual Meeting on Women’s Cancer. Lots of exciting research was presented at the meeting, representing the latest in the care and treatment of women with ovarian and other gynecologic cancers. Highlights from research … Continued
Two studies recently released show a survival benefit for intraperitoneal IP chemotherapy Women with the BRCA1 mutation given IP chemotherapy survived three years longer than those given IV chemotherapy. Read an article about the study here. A study presented at the SGO Annual Meeting showed an improvement in median survival of 10 months.
The New York Times reported today on a study that found most women with ovarian cancer receive inadequate care. The article discusses research presented at the 2013 meeting of the Society of Gynecologic Oncologists (SGO), which found that women are more likely to get optimal care when treated at a medical center that handles a … Continued
Calaneet Balas, OCNA’s Chief Executive Officer, testified before the House Subcommittee on Labor, Health and Human Services, Education, and Related Agencies on Wednesday, March 13. Her remarks touched on the importance of federal funding for ovarian cancer education and research through the National Cancer Institute and Centers for Disease Control and Prevention. Summing up our … Continued
Often, patients enrolled in clinical trials live longer than those who are not, however, a new study shows that the survival benefit may be due to the patient’s health, not the treatment received in the clinical trial. Patients interested in clinical trials may also be more involved in decision making, which some believe affects outcomes. … Continued
For immediate release: February 28, 2013 Washington, DC—The federal government recently released regulations that clarify which preventive services will be covered under the Affordable Care Act without cost sharing for patients enrolled in private insurance plans. Preventive services are provided without cost sharing to people enrolled in private plans that were established after August 1, … Continued
Michele Robinson came up with the idea for her cancer support group, “You’ll Never Walk Alone,” during her first chemotherapy treatment for ovarian cancer in November 2004. “I was looking around the room and that song popped into my head. It was true—even though you do experience cancer yourself, no one knows what you feel … Continued
Get email updates about research news, action alerts, and ways to join the fight.
